Roche’s changing plans show how MFN is complicating European drug launches — Live Feedhttps://www.live-feeds.com/feed/roche-s-changing-plans-show-how-mfn-is-complicating-european-drug-launchesContinuously updated, source-cited coverage. Most Favored Nation Drug Policy Forces Shifting European Launcheshttps://www.live-feeds.com/feed/roche-s-changing-plans-show-how-mfn-is-complicating-european-drug-launcheshttps://www.live-feeds.com/feed/roche-s-changing-plans-show-how-mfn-is-complicating-european-drug-launches#u169984Mon, 02 Nov 2026 12:30:56 +0000United States Most Favored Nation drug pricing policies are forcing major pharmaceutical companies like Roche and Novartis to alter their European launch strategies. Roche delayed filing for European approval of its breast cancer pill giredestrant. Novartis CEO Vasant Narasimhan warned that bypassing European health systems entirely is not off the table due to access delays expected beginning in 2027. Drugmakers are reassessing global launch sequences because U.S. policy links domestic prices to lower prices abroad, complicating traditional market entry pathways.Why it mattersAmerican drug pri